Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 147Lymphoma, Follicular 40Lymphoma, Large B-Cell, Diffuse 37Lymphoma, B-Cell, Marginal Zone 24Recurrence 18Lymphoma, Mantle-Cell 17Lymphoma 17Neoplasms, Plasma Cell 15Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 11Neoplasms 9Smoldering Multiple Myeloma 8Lymphoma, B-Cell 8Neoplasm, Residual 5Burkitt Lymphoma 5Leukemia, Plasma Cell 4Waldenstrom Macroglobulinemia 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Plasmacytoma 2Pancreatic Neoplasms 2Neuroblastoma 2Lymphoma, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Hematologic Diseases 2Urinary Bladder Neoplasms 1

Interventions

Brentuximab Vedotin 2Lenalidomide 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Primary Cutaneous Anaplastic Large Cell × Lenalidomide × 1 year × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡